Fresh analysis suggests that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end traditional lifestyle programs.
Research printed in a prominent health publication points out that while obese people frequently drop a large proportion of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying such medications should be informed of the potential of fast weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight in about one and a half years.
Weighing Approaches
The study, which reviewed 37 of studies involving thousands of patients, contrasted the results of the injectable medications with other pills.
Scientists emphasize that people who lose weight through lifestyle changes alone typically have a more gradual weight regain—approximately 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Doctors believe the way of the drugs is key to understanding the heightened rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone levels several times higher than normal might result in the body to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication leads to appetite is no longer kept in check, making binge eating much more probable."
A Chronic Condition?
The NHS suggest the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the high risk of weight regain, the therapy is often ongoing.
This perspective is echoed by drug manufacturers, who state that the results "underscore the persistent nature of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
Users who have stopped the jabs describe a intense resurgence of hunger.
"It was like a trigger activating and you're instantly extremely hungry," recalled an individual.
This challenge is exacerbated if users have not developed sustainable lifestyle or habit changes during treatment.
Significant Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with interest remaining high.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone solution and long-term success likely depends on integrated behavioural support.
